Results 231 to 240 of about 2,276,968 (394)

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Regional Emergence of Water-Related Browning in a Greening World. [PDF]

Glob Chang Biol
Orth R, Denissen JMC, Kroll J, O S, Bastos A, Li W, Miralles DG, Ruiz-Vásquez M, Hoek van Dijke AJ, Feldman AF, Migliavacca M, Wang-Erlandsson L, Stocker BD, Teuling AJ, Yang H, Zhan C, Yu X.   +16 more
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Limited phosphate resources are efficiently allocated to each organ by the PHR1-EIN3/EIL1 module to coordinate their establishment. [PDF]

Sci Adv
Yu FH, Gu CY, Wang YB, Mu XR, Bao QX, Sai N, Yang Y, Qi J, Yang M, Meng LS.   +9 more
europepmc   +1 more source

Greening Income Support and Supporting Green [PDF]

A multitude of design decisions influence the performance of voluntary conservation programs. This Economic Brief is one of a set of five exploring the implications of decisions policymakers and program managers must make about who is eligible to receive
Claassen, Roger, Morehart, Mitchell J.
core   +1 more source

MSPA-based green space morphological pattern and its spatiotemporal influence on land surface temperature [PDF]

Ming Chen, Yubo Sun, Bo Yang, Jiayi Jiang   +3 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Light interacts with mechanical stress to regulate the seed-to-seedling transition. [PDF]

Stress Biol
Meng Y, Wu J, Iqbal J, Sajid S, Wu Q.
europepmc   +1 more source

ASSESSMENT OF THE PRESENT LEVEL OF THE MAIN COMPOUNDS OF POLLUTANT EMISSIONS FROM INLAND WATERWAY TRANSPORT SYSTEM IN THE DANUBE REGION WETLANDS-GREEN DANUBE

, 2021
Iuliana-Mihaela Tudor, Vasile Pipirigeanu, Doina Munteanu, Marian Tudor, Adrian Burada, Orhan Ibram, Liliana Teodorof, Cristina Despina, Marian Mierlă, Cristian Trifanov, Ciprian Anore, Diana Bota, Ovidiu Cupşa, Mihaela Vintila, Natalia Budescu, Rafael Robert, Eppich Markus, Peter Szuppinger, Valeri Stoyanov Penchev   +18 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source